Press Releases: 2017

ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration

December 19, 2017
Leiden, The Netherlands, December 18, 2017, - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, and Regeneron P...
Read more
ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration

Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

November 28, 2017
Maastricht, The Netherlands, 28 November 2017 - Cristal Therapeutics, a clinical stage biopharmaceutical company developing tar...
Read more
Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference

November 07, 2017
7 November 2017, Windsor, UK: Macrophage Pharma Limited ('MPL') the immuno-oncology research and development company focused on...
Read more
Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference

Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours

November 01, 2017
Maastricht, The Netherlands, 1 November 2017 - Cristal Therapeutics, a clinical stage biopharmaceutical company developing targ...
Read more
Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours

Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz

October 26, 2017
- Ceremony Conventio Medicinae held at University Medical Center Leiden, The Netherlands, October 26, 2017 - ISA Pharmaceuti...
Read more
Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz

Phase I results with ModraDoc006/r published in the European Journal of Cancer

October 15, 2017
14 october 2017 Researchers from the Netherlands Cancer Institute have published results from a Phase I study with oral do...
Read more
Phase I results with ModraDoc006/r published in the European Journal of Cancer

Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017

September 04, 2017
Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor Leiden, The Netherlands, Sep...
Read more
Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017

Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures

August 23, 2017
Merck Ventures Joins Investment Syndicate and the Board of Macrophage 23 August 2017, Windsor, UK: Macrophage Pharma Limited ('MPL') the immuno-oncology research and development company focused on macroph...
Read more

U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron

July 28, 2017
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company...
Read more
U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron

Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer

June 14, 2017
Amsterdam, The Netherlands June 14, 2017 - Modra Pharmaceuticals today announced the initiation and the inclusion of the first patients in a Phase II study of its lead compound, ModraDoc006/r, in metastatic...
Read more

Inthera Bioscience raises CHF 10.5 million in Series A financing round

June 01, 2017
Zurich, Switzerland, May 31, 2017 - Inthera Bioscience, a Swiss biopharmaceutical company developing first-in-class targeted sm...
Read more
Inthera Bioscience raises CHF 10.5 million in Series A financing round

Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017

May 23, 2017
• Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer Leiden, The Netherlands, May 23, 2017 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy c...
Read more

Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer

May 17, 2017
Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initia...
Read more
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer

Macrophage Pharma Appoints Development Director

May 11, 2017
Dr Joanne Bedwell-Garner joins management team Windsor, England, May 11, 2017.  Macrophage Pharma Limited ('MPL') the immuno-o...
Read more
Macrophage Pharma Appoints Development Director

CIMT to honor Dutch immuno-haematologist Cornelis Melief with lifetime achievement award

May 10, 2017
On May 10, 2017, the Dutch immuno-haematologist Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in...
Read more
CIMT to honor Dutch immuno-haematologist Cornelis Melief with lifetime achievement award

Merus Named BioCapital Europe 2017 Company of the Year

March 16, 2017
Award Recognizes Company's Substantial Transformation and Breakthroughs Over Past 12 Months UTRECHT, The Netherlands, March...
Read more
Merus Named BioCapital Europe 2017 Company of the Year

Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC

February 16, 2017
- First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer Leiden, The Netherlands, Februar...
Read more
Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC

Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies

January 23, 2017
UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closi...
Read more

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

January 19, 2017
Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures. Funding used: - to execute clinical phase Ib and phase...
Read more
Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform

January 09, 2017
WINDSOR, England, January 9, 2017 /PRNewswire/ -- Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financi...
Read more
1 2 Next

Home > Press Releases > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds